Abbott Labs personnel changes
This article was originally published in The Gray Sheet
Olivier Bouhon appointed senior VP-European operations, Jaime Contreras VP-Latin American diagnostic commercial operations, firm announces June 17. Separately, Abbott reps Jose Rivera, Rick Gonzalez and Rob Gasaway meet with FDA Chief Counsel Daniel Troy June 10 in Rockville, Md. to discuss issues related to company's 1999 consent decree (1"The Gray Sheet" Nov. 8, 1999, p. 4)...
You may also be interested in...
Abbott Laboratories' AFP and CA 125 diagnostic cancer tests are among the diagnostic products deemed "medically necessary" by FDA and will continue to be made available under the company's Nov. 2 consent decree with the agency.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.